Fig. 3: Blood vessel density within the tumors after Regorafenib treatment. | British Journal of Cancer

Fig. 3: Blood vessel density within the tumors after Regorafenib treatment.

From: Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis

Fig. 3: Blood vessel density within the tumors after Regorafenib treatment.The alternative text for this image may have been generated using AI.

a + c Percentage of CD31-positive cells in the tumors. Boxplot data are presented as mean ± SD by Mann–Whitney U test. No statistical difference was found. b + d Representative CD31-staining of PEG- and Regorafenib- treated mice during tumor development (PEG: n = 6; Rego: n = 8) and tumor progression (PEG: n = 7; Rego: n = 10).

Back to article page